Skip to main content
. Author manuscript; available in PMC: 2016 Jul 1.
Published in final edited form as: Exp Hematol. 2015 Apr 24;43(7):537–545.e11. doi: 10.1016/j.exphem.2015.03.006

Table 1.

Summary of JAK family inhibitors.

Inhibitor name Company JAK1 JAK2 JAK3 TYK2 Citation
BMS-911543 Bristol-Myers Squibb 356 1 73 66 Purandare et al., 2012
ruxolitinib (INCB018424) Novartis 3.3 2.8 428 19 Quintas-Cardama et al., 2010
TG101209 Sanofi-Aventis ND 6 169 ND Pardanani et al., 2007
tofacitinib (CP-960,550) Pfizer 112 20 1 ND Changelian et al., 2003
pacritinib (SB1518) S*BIO 1280 23 520 50 William et al., 2011
momelotinib (CYT387) Gilead 11 18 155 17 Tyner et al., 2010